Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands; Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands; Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
Am J Cardiol. 2020 Jul 1;126:16-22. doi: 10.1016/j.amjcard.2020.03.050. Epub 2020 Apr 7.
Identifying coronary artery disease (CAD) in atrial fibrillation (AF) patients improves risk stratification and defines clinical management. However, the value of screening for subclinical CAD with cardiac CT in AF patients is unknown. Between 2011 and 2015, 94 consecutive patients without known or suspected CAD (66 (57-73) years, 68% male), who were referred for AF evaluation, underwent a noncontrast-enhanced coronary calcium scan and a coronary computed tomography angiography (CCTA) at our center. We retrospectively evaluated the coronary calcium score, the prevalence of obstructive CAD (≥50% stenosis) determined by CCTA, compared clinical management and 5-year outcome in patients with and without obstructive CAD on CCTA, and examined the potential impact of a coronary calcium score and obstructive CAD on CCTA as a manifestation of vascular disease on the CHA2Ds2VASc score and for the cardiovascular risk stratification of AF patients. The median coronary calcium score was 57 (0-275) and 24 patients (26%) had obstructive CAD on CCTA. At baseline, patients with obstructive CAD more often used statins than those without obstructive CAD (54% vs 26%, p = 0.011). After a median clinical follow-up of 2.4 (0.5-4.5) years, patients with obstructive CAD more frequently used oral anticoagulant and/or antiplatelet drugs, statins, angiotensin-II-receptor blockers and/or angiotensin-converting-enzyme inhibitors, and less often used class I antiarrhythmic drugs than patients without obstructive CAD (all p <0.050). After a median follow-up of 5.7 (4.8-6.8) years, mortality was higher in patients with obstructive CAD than in those without obstructive CAD (29% vs 11%, log-rank test: p = 0.034). Implementation of a coronary calcium score and/or obstructive CAD on CCTA elevated the CHA2Ds2VASc score and cardiovascular risk stratification in 42 patients (p <0.001) and 47 patients (p = 0.006), respectively. In conclusion, we observed a high prevalence of obstructive CAD on CCTA in AF patients without known or suspected CAD. AF patients with obstructive CAD were managed differently and had a worse prognosis than those without obstructive CAD. Cardiac CT could enhance cardiovascular risk stratification of AF patients.
在心房颤动(AF)患者中识别冠状动脉疾病(CAD)可改善风险分层并确定临床管理。然而,在 AF 患者中使用心脏 CT 筛查亚临床 CAD 的价值尚不清楚。在 2011 年至 2015 年间,94 例连续的无已知或疑似 CAD(66 岁(57-73 岁),68%为男性)的患者因 AF 评估而在我院接受了非增强冠状动脉钙扫描和冠状动脉计算机断层扫描血管造影(CCTA)。我们回顾性评估了冠状动脉钙评分,根据 CCTA 确定的阻塞性 CAD(≥50%狭窄)的患病率,比较了 CCTA 上有和没有阻塞性 CAD 的患者的临床管理和 5 年结果,并检查了冠状动脉钙评分和阻塞性 CAD 的潜在影响作为血管疾病的表现对 CHA2Ds2VASc 评分和 AF 患者的心血管风险分层的影响。中位冠状动脉钙评分为 57(0-275),24 例(26%)患者的 CCTA 有阻塞性 CAD。在基线时,有阻塞性 CAD 的患者比没有阻塞性 CAD 的患者更常使用他汀类药物(54% vs 26%,p = 0.011)。在中位临床随访 2.4(0.5-4.5)年后,有阻塞性 CAD 的患者更频繁地使用口服抗凝药和/或抗血小板药物、他汀类药物、血管紧张素 II 受体阻滞剂和/或血管紧张素转换酶抑制剂,而较少使用 I 类抗心律失常药物与无阻塞性 CAD 的患者相比(所有 p <0.050)。在中位随访 5.7(4.8-6.8)年后,有阻塞性 CAD 的患者死亡率高于无阻塞性 CAD 的患者(29% vs 11%,对数秩检验:p = 0.034)。在 42 例(p <0.001)和 47 例(p = 0.006)患者中,实施冠状动脉钙评分和/或 CCTA 上的阻塞性 CAD 分别升高了 CHA2Ds2VASc 评分和心血管风险分层。总之,我们在无已知或疑似 CAD 的 AF 患者中观察到 CCTA 上阻塞性 CAD 的高患病率。与无阻塞性 CAD 的患者相比,有阻塞性 CAD 的 AF 患者的治疗方式不同,预后更差。心脏 CT 可以增强 AF 患者的心血管风险分层。